



- (51) International Patent Classification:
C12Q 1/68 (2006.01)
- (21) International Application Number:
PCT/US2014/048807
- (22) International Filing Date:
30 July 2014 (30.07.2014)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/865,754 14 August 2013 (14.08.2013) US
- (71) Applicant: **PRIMERADIX, INC.** [US/US]; Suite 200, 171 Forbes Boulevard, Mansfield, Massachusetts 02048 (US).
- (72) Inventors: **KONG, Lilly I.**; 2524 Palomino Drive, Covina, California 91724 (US). **DIVAKAR, Kiran Madanahally**; 27 Mercury Drive, Shrewsbury, Massachusetts 01545 (US).
- (74) Agents: **FITZGERALD, Mark J.** et al.; Nixon Peabody LLP, 100 Summer Street, Boston, Massachusetts 02110 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

[Continued on next page]

- (54) Title: COMPOSITIONS AND METHODS FOR MULTIPLEX ANALYSIS OF NRAS AND BRAF NUCLEIC ACIDS





Fig. 1

(57) Abstract: Described herein are methods and assays relating to the detection of NRAS and/or BRAF alterations (e.g. variations in copy number and expression level, and/or the presence of mutations, including point mutations). Existing methods are limited in their clinical usefulness by, e.g., limited sensitivity, inter-lab discordance, or inability to provide the necessary multiplex ability. The methods and assays provided herein permit multimodal, multiplex assaying for faster, more cost-effective testing and screening of patients, permitting improved health-care.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). **Published:**

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
 - *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *with international search report (Art. 21(3))*
 - *with sequence listing part of description (Rule 5.2(a))*